Drug Search Results
More Filters [+]

Sivelestat

Alternative Names: sivelestat
Latest Update: 2024-01-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ELA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: China | Korea

Approved Indications: None

Known Adverse Events: None

Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sivelestat

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Acute Lung Injury|Acute Respiratory Distress Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20210072

P1

Recruiting

Acute Respiratory Distress Syndrome|Acute Lung Injury

None

Recent News Events